Glycogen synthase kinase-3 alpha

Glycogen synthase kinase-3 alpha (GSK-3α) is a constitutively active protein kinase that serves as a negative regulator of glucose homeostasis, Wnt signaling, and transcription factor activity (UniProt: P49840). It phosphorylates and inactivates key substrates including glycogen synthase, β-catenin, and APC, thereby controlling glycogen synthesis, cell proliferation, and neuronal polarity. GSK-3α also facilitates amyloid precursor protein processing and amyloid-β generation, linking it mechanistically to Alzheimer's disease pathology.

GSK-3α is expressed broadly across tissues and participates in insulin signaling, autophagy regulation, and apoptosis control through phosphorylation of diverse substrates such as MCL1, KAT5/TIP60, and RICTOR. The protein operates at critical intersections of metabolic and developmental signaling pathways, with particular importance in liver glycogen metabolism and neuronal development.

In Alzheimer's disease, GSK-3α is significantly downregulated in post-mortem AD brain tissue compared to age-matched controls, with a mean log2 fold-change of −0.84 across subcellular fractions (Chaparral AD proteomics). This downregulation contrasts with GSK-3α's well-documented role in promoting APP processing and amyloid plaque formation, suggesting compensatory or pathological shifts in kinase activity may occur during AD neurodegeneration.